Payment overview · 2025
General Payments
$452.26
23 reported records · 10 companies
Healthcare provider profile · identity verified
Breton L Morgan, MD
Allopathic & Osteopathic Physicians|Family Medicine · PT PLEASANT, WV · NPI 1508897919
Verified facts
What the public records show
CMS Open Payments records show Breton L Morgan, MD received $452.26 in general payments during 2025 across 23 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.12 | 19.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.62 | 17.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.91 | 15.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.01 | 13.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.73 | 8.1% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $36.66 | 8.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.42 | 7.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.42 | 4.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.86 | 3.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.51 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $452.26 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.12 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.62 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.01 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 400 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 103 |
| Prednisone | Prednisone | 257 | 101 |
| Omeprazole | Omeprazole | 236 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 80 |
| Diazepam | Diazepam | 228 | 34 |
| Furosemide | Furosemide | 201 | 79 |
| Potassium Chloride | Potassium Chloride | 193 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 72 |
| Alprazolam | Alprazolam | 174 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 52 |
| Losartan Potassium | Losartan Potassium | 146 | 45 |
| Mounjaro | Tirzepatide | 140 | 29 |
| Famotidine | Famotidine | 136 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 47 |
| Cefdinir | Cefdinir | 120 | 72 |
| Lorazepam | Lorazepam | 117 | 16 |
| Lisinopril | Lisinopril | 113 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 98 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 27 |
| Metformin Hcl | Metformin Hcl | 92 | 32 |
| Sertraline Hcl | Sertraline Hcl | 89 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 43 |
| Clonazepam | Clonazepam | 85 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 59 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 44 |
| Ozempic | Semaglutide | 81 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 26 |
| Methylprednisolone | Methylprednisolone | 78 | 51 |
| Tramadol Hcl | Tramadol Hcl | 78 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | suppressed |
| Simvastatin | Simvastatin | 76 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 27 |
| Meloxicam | Meloxicam | 72 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 29 |
| Trazodone Hcl | Trazodone Hcl | 70 | 24 |
| Montelukast Sodium | Montelukast Sodium | 66 | 21 |
| Ibuprofen | Ibuprofen | 64 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 19 |
| Azithromycin | Azithromycin | 63 | 44 |
| Carvedilol | Carvedilol | 63 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 34 |
| Cephalexin | Cephalexin | 60 | 37 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 22 |
| Eliquis | Apixaban | 58 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 38 |
| Allopurinol | Allopurinol | 54 | 17 |
| Mupirocin | Mupirocin | 54 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 17 |
| Amoxicillin | Amoxicillin | 51 | 21 |
| Pregabalin | Pregabalin | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Fluconazole | Fluconazole | 45 | 20 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Nitroglycerin | Nitroglycerin | 41 | 33 |
| Meclizine Hcl | Meclizine Hcl | 40 | 23 |
| Promethazine Hcl | Promethazine Hcl | 39 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 13 |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 18 |
| Celecoxib | Celecoxib | 32 | 12 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 18 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Finasteride | Finasteride | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 11 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 14 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 11 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $452.26 · 23 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, GLYCATE, LINZESS, Ohtuvayre, Omnipod, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error